INmune Bio, Inc.
INMB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $93 | $202 | $114 | $165 |
| - Cash | $21 | $36 | $52 | $75 |
| + Debt | $0 | $10 | $15 | $15 |
| Enterprise Value | $73 | $177 | $77 | $105 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -91% | -58.6% | 106.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$42 | $0 | $0 | $0 |
| % Margin | -300,585.7% | 0% | 0% | 0% |
| Net Income | -$42 | -$30 | -$27 | -$30 |
| % Margin | -300,585.7% | -19,360% | -7,299.2% | -16,762.4% |
| EPS Diluted | -2.11 | -1.67 | -1.52 | -1.88 |
| % Growth | -26.3% | -9.9% | 19.1% | – |
| Operating Cash Flow | -$33 | -$12 | -$23 | -$29 |
| Capital Expenditures | $0 | $0 | $0 | -$15 |
| Free Cash Flow | -$33 | -$12 | -$23 | -$44 |